Literature DB >> 8393375

Bilateral Wilms tumor. Review of outcome, associated abnormalities, and late effects in 36 pediatric patients treated at a single institution.

P Shearer1, D M Parham, J Fontanesi, M Kumar, T E Lobe, D Fairclough, E C Douglass, J Wilimas.   

Abstract

BACKGROUND: Patients with bilateral Wilms tumor have an increased incidence of associated abnormalities and nephrogenic rests and require individualized multimodality therapy for cure. The authors reported the associated abnormalities, outcome, complications, and late effects of treatment in a group of children with bilateral Wilms tumor treated at St. Jude Children's Research Hospital, Memphis, Tennessee, over a 28-year period.
METHODS: The records of 36 consecutive pediatric patients diagnosed with bilateral Wilms tumor between 1962-1990 were analyzed. Biopsy material was also reviewed, with particular emphasis on characterization of nephrogenic rests and histology.
RESULTS: Twenty-nine patients had synchronous tumors and 7 had metachronous lesions. Associated physical abnormalities were present in 12 patients and involved the genitourinary, cardiovascular, integumentary, and musculoskeletal systems. The overall survival for patients with metachronous tumors (71%) was similar to that for those with synchronous tumors (70%). There was no effect of age or the presence of nephroblastomatosis. Two patients with synchronous tumors initially treated with nephrectomy eventually required bilateral nephrectomies for contralateral recurrence after chemotherapy and radiation therapy. Nephrogenic rests were present in 22 of 30 evaluable patients. Two of three patients with metachronous tumors had intralobar nephrogenic rests. Bilateral renal salvage procedures were demonstrated to be technically feasible and effective in controlling disease without compromising renal function or survival. Late effects included scoliosis in three patients treated before 1970, cardiomyopathy in one patient who received 300 mg/m2 doxorubicin and 12 Gy pulmonary irradiation, and benign tumors in two patients, one of whom also had a bowel obstruction. Serum creatinine, urea nitrogen, and blood pressure were normal in 23 of 26 survivors.
CONCLUSIONS: The authors' experience supports a favorable outcome with minimal late effects for patients with bilateral Wilms tumor who receive individualized therapy at pediatric oncology centers.

Entities:  

Mesh:

Year:  1993        PMID: 8393375     DOI: 10.1002/1097-0142(19930815)72:4<1422::aid-cncr2820720443>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Management of bilateral Wilms tumours.

Authors:  Alastair J W Millar; Sharon Cox; Alan Davidson
Journal:  Pediatr Surg Int       Date:  2017-01-04       Impact factor: 1.827

Review 2.  Management of bilateral Wilms tumours.

Authors:  Alastair J W Millar; Sharon Cox; Alan Davidson
Journal:  Pediatr Surg Int       Date:  2017-05-17       Impact factor: 1.827

3.  Management of Wilms' tumor: NWTS vs SIOP.

Authors:  Sushmita Bhatnagar
Journal:  J Indian Assoc Pediatr Surg       Date:  2009-01

Review 4.  Wilms' tumour. Optimal treatment strategies.

Authors:  K Suryanarayan; N Marina
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

5.  Overall Survival and Renal Function of Patients With Synchronous Bilateral Wilms Tumor Undergoing Surgery at a Single Institution.

Authors:  Andrew M Davidoff; Rodrigo B Interiano; Lynn Wynn; Noel Delos Santos; Jeffrey S Dome; Daniel M Green; Rachel C Brennan; M Beth McCarville; Matthew J Krasin; Kathleen Kieran; Mark A Williams
Journal:  Ann Surg       Date:  2015-10       Impact factor: 12.969

6.  Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the Literature.

Authors:  Sophie E van Peer; Janna A Hol; Alida F W van der Steeg; Martine van Grotel; Godelieve A M Tytgat; Annelies M C Mavinkurve-Groothuis; Geert O R Janssens; Annemieke S Littooij; Ronald R de Krijger; Marjolijn C J Jongmans; Marc R Lilien; Jarno Drost; Roland P Kuiper; Harm van Tinteren; Marc H W A Wijnen; Marry M van den Heuvel-Eibrink
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.